Abstract The leflunomide (CAS 75706-12-6) metabolite (LFM) analog α-cyano-β-hydro-xy-β- methyl-N-(2, 5-dibromophenyl)-propenamide (LFM-A13, DDE-28, CAS 244240-24-2), is a rationally designed inhibitor of the anti-apoptotic enzyme Bruton's tyrosine kinase (BTK). LFM-A13 is being developed as a novel dual-function anti-cancer drug with apoptosis- promoting and anti-thrombotic properties. LFM-A13 was prepared under current Good ...